|
|
 |
 |
 |
 |
   |
DRUG OVERDOSEForgive Ivax shareholders if they're a bit under the weather. Intense competition in generic drugs, Ivax' main business, prompted the Miami-based company to warn on June 27 that quarterly earnings would come in some 74% under expectations. Ivax stock closed down 8 5/8 points that day, at 15 1/4, before recovering to 16 1/4 on July 1. CEO Dr. Phillip Frost doesn't have a magic cure. But he sees promise in proprietary products to treat diabetes and bladder disorders that Ivax may soon launch. EDITED BY KELLEY HOLLAND
|
Updated June 14, 1997 by bwwebmaster
Copyright 1996, by The McGraw-Hill Companies Inc. All rights reserved.
Terms of Use